Saturday, April 29, 20062
Orlistat
GSK is hoping OTC Xenical (Orlistat) will be a blockbuster. Don't expect miracles however. From UptoDate, here is the results of a meta-analysis of the prescription version:
Almost two-thirds of the subjects completed the first year of treatment. Weight loss at one year varied from 5.5 to 6.6 percent of initial body weight in the placebo groups and 8.5 to 10.2 percent in the orlistat groups.
Comments
-
ipanema
In a recent petition it mentioned that FDA is aware of the breast cancer risk as well as possible colon lessions when it initially considered Xenical, but the agency chose to rely on the company's analysis.
-
ipanema
More
Post a CommentMore
FDA spokeswoman said FDA would carefully review the petition. <<< They better be. It's confusing.
10:49 AM
3:23 PM